Small molecule (Molecular glue degrader) · Degrader of cereblon (CRBN) · developed by Celgene
Golcadomide is a small molecule that modulates the CRL4-CRBN E3 ubiquitin ligase by binding cereblon. This directs ubiquitination and proteasome-mediated degradation of certain transcription factors, activating T-lymphocytes. It is being studied in peripheral T-cell lymphoma and follicular helper T-cell lymphoma.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07018752 | Phase 1/2 | Peripheral T Cells Lymphoma (PTCL) | Recruiting | ABBV |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Follicular Helper T-Cell LymphomaPeripheral T Cells Lymphoma (PTCL)
See BMY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
BMY catalysts and pipeline →